WXB SEP6 (WXB2609) News

《Major Brokerage》BofA Securities: China's CXO sector benefits from robust biotech financing; raises target prices for Wuxi Apptec (02359.HK) and others

Bank of America Securities issued a report noting that robust first-half fundraising performance in the global and Chinese biotech primary markets, coupled with sustained activity in out-licensing deals for innovative drugs, is expected to further accelerate R&D activities, benefiting Chinese CRO/CDMO companies. The firm has revised upward its terminal growth rate assumption for the sector from 1% to 3% and raised target prices for several CXO companies. According to Pharmcube data, in the first half of 2026, there were 814 healthcare financing deals in China’s primary market, up 13.8% year-over-year, with total funding amounting to RMB 72.6 billion, an increase of 41.7% year-over-year; among these, innovative drugs

AASTOCKSAug 12 11:28

Zhitong HK Stock Connect Holdings Analysis | August 12

Stock Connect Holdings Analysis | August 11, 2026

Zhitong FinanceAug 12 08:30

GTJA HK Connect Active Trading | August 11

Stock Connect Active Trading | August 11, 2026

Zhitong FinanceAug 11 19:00

Interest in semiconductor industry research has been overtaken.

Recently, innovative pharmaceuticals have experienced a rebound, significantly boosting market interest in the pharmaceutical and biotechnology sector.

cls.cnAug 11 16:18

ZHITONG HK Connect Holdings Analysis | August 11

Stock Connect Holdings Analysis | August 10, 2026

Zhitong FinanceAug 11 08:30

Zhitong Stock Connect Active Trading | August 10

Stock Connect Active Trading | August 10, 2026

Zhitong FinanceAug 10 19:00

Southbound Capital Flows | Southbound capital recorded net purchases of HK$2.021 billion; commercialization of large models reaches an inflection point, with southbound funds adding over HK$1 billion to MINIMAX (00100)

On August 10, southbound capital recorded a net purchase of HK$2.021 billion in the Hong Kong stock market. Specifically, Shanghai-Hong Kong Stock Connect saw a net purchase of HK$2.796 billion, while Shenzhen-Hong Kong Stock Connect recorded a net sale of HK$776 million.

Zhitong FinanceAug 10 17:48

Hong Kong Market Midday Review | All three major indices rose, with the Hang Seng Index up 0.72%; tech and internet stocks broadly advanced, Alibaba gaining over 2%; biotech stocks climbed, with Wuxi Apptec rising nearly 3% to hit a new intraday high; Guo

Tech and internet stocks rose, with Alibaba-W up 2.10% and JD.com-SW up 1.80%; coal stocks advanced, with Jinma Energy surging 20.83% and Power Development rising 8.95%; Hong Kong retail stocks gained, with Bonjour Holdings down 8.00% and Chow Sang Sang up 6.69%;

Futu NewsAug 10 12:10

Double positive catalysts boost pharmaceutical stocks! Wuxi Apptec’s Hong Kong shares hit a record high.

① Wuxi Apptec has obtained a preliminary injunction shielding it from the immediate effects of a Section 1260H designation—what do industry insiders think? ② Against the backdrop of sustained strong BD deal activity in outbound innovative drug transactions, how do institutional investors view pharmaceutical stocks?

cls.cnAug 10 11:32

Wuxi Apptec scores a阶段性 victory in its legal countermeasures against the Section 1260H list! The 'Wuxi-linked exposure'—nearly 30%—propels the index underlying the Tianhong Innovation Drug ETF (517380) to surge nearly 4% again, bringing its year-to-date g

Gelonghui, August 10 — The innovative drug sector continued its upward momentum from last Friday, with Wuxi Apptec’s A-shares rising over 5% and H-shares gaining more than 4%, driving a strong 3.97% increase in the underlying index of the Tianhong Innovative Drug ETF (517380). Year-to-date, the index has climbed 20.91%, ranking among the top performers in the innovative drug segment. The ETF has also attracted significant investor interest, recording net inflows for three consecutive days and accumulating RMB 330 million in inflows over the past 20 trading days. The Tianhong Innovative Drug ETF (517380) tracks the Hang Seng CSI HKex Select 50 Innovative Drug Index, whose methodology demonstrates clear competitive advantages: ① CXO companies are systematically prioritized for inclusion, as the index methodology explicitly states "

Gelonghui FinanceAug 10 10:23

HK Market Movers | CRO Concept Stocks Lead Gains; Wuxi Apptec (02359) Secures Preliminary Injunction from U.S. Court, Halting Enforcement of DoD’s Section 1260H Designation

CRO-related stocks led the gains. As of the time of writing, GenScript Biotech (01548.HK) rose 6.44% to HK$24.46; Wuxi Apptec (02359.HK) gained 5.36% to HK$202.80; Wuxi Bio (02269.HK) climbed 5.02% to HK$48.16; and Pharmaron (03759.HK) increased by 4.15% to HK$28.62.

Zhitong FinanceAug 10 09:56

Zhitong Stock Connect Active Trading | August 7

Stock Connect Active Trading | August 7, 2026

Zhitong FinanceAug 7 19:00

China Trade Results, Persian Gulf Uncertainties Roil Asian Stock Markets

Asian stock markets churned on Friday, as strong trade figures from Beijing boosted China-exposed exchanges, but other trading floors tracked lower on tech-sector weakness and Persian Gulf concerns.

MT NewswiresAug 7 18:33

Southbound Capital Flows | Southbound capital recorded a net sell-off of HK$778 million; continued accumulation of MINIMAX (00100) with combined purchases over two days exceeding HK$4.9 billion

On August 7, southbound capital recorded a net selling of HK$778 million in the Hong Kong stock market. Of this, Stock Connect (Shanghai) reported a net buying of HK$571 million, while Stock Connect (Shenzhen) reported a net selling of HK$1.349 billion.

Zhitong FinanceAug 7 17:48

ETF Market Movement | CSOP Hang Seng Tech Index ETF (03174) Rises Over 5% as Leading Innovative Drugmakers Report Strong Earnings, Global Industry Chain Sentiment Remains Elevated

CSOP Hang Seng Tech Index ETF (03174.HK) rose more than 5%. As of the time of writing, it was up 5.4% at HK$3.628, with a trading volume of HK$7.2374 million.

Zhitong FinanceAug 7 14:56

Most innovative drug-related stocks rose, as innovative pharmaceutical companies enter their earnings announcement window, and upcoming academic conferences are expected to provide a series of catalysts.

According to data from the National Medical Products Administration (NMPA), China recorded 81 outbound licensing deals for innovative drugs in the first half of the year, with a total transaction value of approximately USD 110 billion—already reaching 80% of the full-year 2025 level and setting a new record high for a half-year period. Disclosure of clinical data at top-tier international medical conferences is expected to serve as a key near-term catalyst. The World Conference on Lung Cancer (WCLC) has already released abstract titles and will publish full data on August 19; meanwhile, the European Society of Cardiology (ESC) annual congress at the end of August will feature pivotal cardiovascular clinical trial results. Bohai Securities notes that August marks the semi-annual earnings reporting season and recommends prioritizing sectors likely to benefit from earnings-driven catalysts. Furthermore, the firm maintains a long-term positive outlook on the development trajectory of domestically developed innova

Zhitong FinanceAug 7 13:28

Express News | Most Hong Kong-listed innovative drug stocks rose, with Zai Lab surging over 14%, Wuxi Bio gaining more than 6%, Wuxi Apptec rising nearly 6%, and Ascletis Pharma and Confo Therapeutics each climbing over 4%.

BreakingsAug 7 11:04

Transcenta Holding-B (06628.HK) plans to sell its CDMO assets for a total consideration of RMB 190 million.

Gelonghui, August 7 — Transcenta Holding Limited (HKEX: 06628) announced that on August 6, 2026, the seller (Hangzhou Yian Jishi Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company) entered into an asset purchase agreement with the buyer (Hangzhou Mingde Biomedical Technology Co., Ltd., a wholly-owned subsidiary of WuXi Biologics), pursuant to which the seller has conditionally agreed to sell, and the buyer has conditionally agreed to purchase, CDMO assets for a total consideration of RMB 190 million (subject to adjustment as set forth in the asset purchase agreement). Following the completion of Phase II, the Company will no longer hold any interest in the CDMO assets.

Gelonghui FinanceAug 7 06:49

Wuxi Biologics (Cayman) Stock Advances 1.9% in Hong Kong

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Wuxi Biologics (Cayman) Inc. rallied 1.9% to 41.38 Hong Kong dollars on what proved to be an

Dow JonesAug 6 16:33

CITIC Securities: The CXO sector’s beta is stabilizing and trending positively, with new domestic CRO/CDMO orders and earnings expected to accelerate growth by 2026.

The bank believes that new orders and earnings in China's CRO/CDMO sector will accelerate in 2026, driving the CXO industry chain into a new phase of development.

Zhitong FinanceAug 6 15:31